ID: ALA2334662

Max Phase: Preclinical

Molecular Formula: C20H18O4

Molecular Weight: 322.36

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc(O)c(C(=O)O)c(CCc2ccc3ccccc3c2)c1

Standard InChI:  InChI=1S/C20H18O4/c1-24-17-11-16(19(20(22)23)18(21)12-17)9-7-13-6-8-14-4-2-3-5-15(14)10-13/h2-6,8,10-12,21H,7,9H2,1H3,(H,22,23)

Standard InChI Key:  IWNNQMBHKDWYJC-UHFFFAOYSA-N

Associated Targets(Human)

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HEK293 82097 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Staphylococcus aureus 210822 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Transcription factor SOX-18 84 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 322.36Molecular Weight (Monoisotopic): 322.1205AlogP: 4.04#Rotatable Bonds: 5
Polar Surface Area: 66.76Molecular Species: ACIDHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 2.93CX Basic pKa: CX LogP: 5.35CX LogD: 1.86
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.74Np Likeness Score: 0.60

References

1. Mamidyala SK, Ramu S, Huang JX, Robertson AA, Cooper MA..  (2013)  Efficient synthesis of anacardic acid analogues and their antibacterial activities.,  23  (6): [PMID:23416004] [10.1016/j.bmcl.2013.01.074]
2.  (2018)  Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases,